InsiderSignal.AI

InsiderSignal.ai

CRSP - Crispr Therapeutics AG

Insider Sale by Patel Naimish (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Patel Naimish, serving as Chief Medical Officer at Crispr Therapeutics AG (CRSP), sold 3,150 shares at $48.26 per share, for a total transaction value of $152,019.00. Following this transaction, Patel Naimish now holds 13,143 shares of CRSP.

This sale represents a 19.00% decrease in Patel Naimish's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 17, 2026, 1 day after the trade was made.

Crispr Therapeutics AG operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Patel Naimish

Patel Naimish

Chief Medical Officer

Naimish Patel, M.D. (age 53) is the Chief Medical Officer of CRISPR Therapeutics AG (CRSP), appointed on May 28, 2024.[[1]](https://fintool.com/app/research/companies/CRSP/people/naimish-patel)[[2]](https://crisprtx.com/about-us/leadership/naimish-patel-m-d)[[5]](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-strengthens-executive-leadership-team-with-key-appointments) He joined from Sanofi, where he served as Global Development Therapeutic Area Head of Immunology & Inflammation (2019–2024), leading pipeline development across respiratory, dermatology, GI, and rheumatology areas, and oversaw business development and M&A; prior to that, he was Global Program Head for dupilumab (Dupixent), driving indication expansions including COPD and eosinophilic esophagitis.[[1]](https://fintool.com/app/research/companies/CRSP/people/naimish-patel)[[2]](https://crisprtx.com/about-us/leadership/naimish-patel-m-d) Dr. Patel previously held clinical development and discovery roles at AstraZeneca and Vertex Pharmaceuticals, and served as faculty at Harvard Medical School and Beth Israel Deaconess Medical Center (BIDMC), leading an NIH-funded lab in translational immunology focused on innate lung defense.[[1]](https://fintool.com/app/research/companies/CRSP/people/naimish-patel)[[2]](https://crisprtx.com/about-us/leadership/naimish-patel-m-d) He earned a B.S. in Mechanical Engineering from MIT and an M.D. from McGill University, completed internal medicine residency at Columbia-Presbyterian Hospital, and pulmonary & critical care fellowship at Harvard/BIDMC.[[1]](https://fintool.com/app/research/companies/CRSP/people/naimish-patel)[[2]](https://crisprtx.com/about-us/leadership/naimish-patel-m-d) In 2025, as CMO, he purchased 1,508 CRSP shares at $32.96 each.[[4]](https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-fec20d81f3b4.html)

View full insider profile →

Trade Price

$48.26

Quantity

3,150

Total Value

$152,019.00

Shares Owned

13,143

Trade Date

Monday, March 16, 2026

1 days ago

SEC Filing Date

Tuesday, March 17, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Crispr Therapeutics AG

Company Overview

No company information available
View news mentioning CRSP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4869052

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime